IMVT

Immunovant is a pre-revenue, clinical-stage immunology company whose value rests entirely on IMVT-1402, a potentially best-in-class anti-FcRn antibody for IgG-mediated autoimmune diseases. The financials are pure cash-burn: no product revenue, a -$506M net loss (EPS -$2.77), -$407M operating cash burn, and a -$1.75B accumulated deficit. The company itself states current funds 'will not be sufficient' to complete development and launch across all indications it is evaluating, and expects to keep incurring losses for the foreseeable future.

The pipeline has genuine promise but also fresh risk. IMVT-1402 showed deep, dose-dependent IgG reductions (~80% target) with a favorable safety profile in Phase 1, and the company is running potentially registrational trials across six indications (Graves' disease, difficult-to-treat RA, MG, CIDP, Sjogren's, plus a CLE proof-of-concept). But in April 2026 the predecessor antibody batoclimab missed the primary endpoint in two Phase 3 thyroid-eye-disease studies, prompting Immunovant to discontinue batoclimab entirely and concentrate solely on IMVT-1402 — concentrating risk into a single asset whose pivotal Graves' disease readouts are not expected until calendar 2027.